API | neramexane

neramexane Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Neramexane is a drug related to memantine, which acts as an NMDA antagonist and has neuroprotective effects. It is being developed for various possible applications, including treatment of tinnitus, Alzheimer's disease, drug addiction and as an analgesic. Animal studies have also suggested antidepressant and nootropic actions, so there are a wide range of potential applications this drug may be used for. It also acts as a nicotinic acetylcholine receptor antagonist. ^Wikipedia

Chemistry

SMILES: CC1(C)CC(C)(C)CC(C)(N)C1
InChIKey: OGZQTTHDGQBLBT-UHFFFAOYSA-N
Mol. Mass: 169.31
ALogP: 2.94 Partition coefficient
ChEMBL Molecule:
neramexane

More Chemistry

Pharmacology

Mechanism of Action:
- Glutamate receptor ionotropic, NMDA 3A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-amino-1,3,3,5,5-pentamethylcyclohexane hydrochloride | mrz 2579 | mrz 2 579 | mrz 2-579 | mrz-2579 | neramexane

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Alzheimer Disease (Phase 3)

Healthy Volunteers (Phase 1)

Metabolism (Phase 1)

Tinnitus (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue